Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

Prof Robert M Anthenelli, MD, Prof Neal L Benowitz, MD, Prof Robert West, PhD, Lisa St. Aubin, DVM, Thomas McRae, MD, David Lawrence, PhD, John Ascher, MD, Cristina Russ, MD, Alok Krishen, MS, Prof A Eden Evins, MD, MPH

University of California, San Diego, California, USA (Prof RM Anthenelli MD ranthenelli@ucsd.edu); University of California, San Francisco, California, USA (Prof NL Benowitz MD neal.benowitz@ucsf.edu); University College, London, UK (Prof R West PhD robert.west@ucl.ac.uk); Pfizer, New York, New York, USA (L St. Aubin DVM lisa.b.staubin@pfizer.com, T McRae MD Thomas.McRae@pfizer.com, D Lawrence PhD David.Lawrence@pfizer.com, C Russ MD Cristina.Russ@pfizer.com); GSK, Research Triangle Park, North Carolina, USA (J Ascher MD john.a.ascher@gsk.com); PAREXEL International on behalf of GSK, Research Triangle Park, North Carolina, USA (A Krishen MS alok.krishen@parexel.com); Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA (Prof Eden Evins MD, MPH a_eden_evins@hms.harvard.edu)

Correspondence to:

Prof Robert M Anthenelli, Department of Psychiatry, University of California, San Diego, Health Sciences, 9500 Gilman Drive, La Jolla, CA 92093-0603, USA

ranthenelli@ucsd.edu

Short title: Neuropsychiatric Safety and Efficacy of First-Line Smoking Cessation Aids

Summary

Background Significant concerns have been raised about the neuropsychiatric safety of the smoking cessation medications, varenicline and bupropion. Their efficacy relative to nicotine patch largely relies on indirect comparisons, and there is limited information on safety and efficacy in smokers with psychiatric disorders. We compared the relative neuropsychiatric safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without psychiatric disorders.

Methods Randomised, double-blind, triple-dummy, placebo- and active- (nicotine patch; 21 mg per day with taper) controlled trial of varenicline (1 mg twice daily) and bupropion (150 mg twice daily) for 12 weeks with 12-week non-treatment follow-up conducted at 140 centres (clinical trial centres, academic centres, and outpatient clinics) in 16 countries between November 2011 and January 2015. Participants were motivated-to-quit smokers with (N=4116) and without (N=4028) psychiatric disorders who received brief cessation counselling at each visit. Randomisation was computer generated (1:1:1:1 ratio). Participants, investigators, and research personnel were blinded to treatment assignments. The primary endpoint was the incidence of a composite measure of moderate and severe neuropsychiatric adverse events. The main efficacy endpoint was biochemically-confirmed continuous abstinence for weeks 9–12. The trial is now closed.

Findings In the non-psychiatric cohort, participants reporting moderate and severe neuropsychiatric adverse events were 13 (1·3%) for varenicline (n=990), 22 (2·2%) for bupropion (n=989), 25 (2·5%) for nicotine patch (n=1006), and 24 (2·4%) for placebo (n=999). The varenicline–placebo and bupropion–placebo risk differences (RDs) for moderate and severe neuropsychiatric adverse events were −1·28 (95% CI −2·40 to −0·15) and −0·08 (−1·37 to 1·21), respectively; the RDs for comparisons with nicotine patch were −1·07 (−2·21 to 0·08) and 0·13 (−1·19 to 1·45), respectively. In the psychiatric cohort, moderate and severe neuropsychiatric adverse events were reported in 67 (6·5%) participants for varenicline (n=1026), 68 (6·7%) for bupropion (n=1017), 53 (5·3%) for

nicotine patch (n=1016), and 50 (4·9%) for placebo (n=1015). The varenicline–placebo and bupropion–placebo RDs were 1·59 (−0·42 to 3·59) and 1·78 (−0·24 to 3·81), respectively; the RDs for contrasts with nicotine patch were 1·22 (−0·81 to 3·25) and 1·42 (−0·63 to 3·46), respectively. Varenicline-treated participants achieved higher abstinence rates than those on placebo (odds ratio 3·61 [95% CI 3·07 to 4·24]), nicotine patch (1·68 [1·46 to 1·93]), and bupropion (1·75 [1·52 to 2·01]). Those on bupropion and nicotine patch achieved higher abstinence rates than those on placebo (2·07 [1·75 to 2·45]; and 2·15 [1·82 to 2·54], respectively). Across cohorts, the most frequent adverse events by treatment group were nausea (25·3% [511/2016 participants], varenicline), insomnia (12·2% [245/2006 participants], bupropion), abnormal dreams (12·4% [251/2022 participants], nicotine patch), and headache (9·9% [199/2014 participants], placebo). Efficacy treatment comparison did not differ by cohort.

Interpretation The study did not detect a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo. Varenicline was more effective than placebo, nicotine patch, and bupropion in helping smokers achieve abstinence, while bupropion and nicotine patch were more effective than placebo.

Funding Pfizer and GlaxoSmithKline.

Trial registration clinicaltrials.gov identifier: NCT01456936.

Research in context

Evidence before this study

We searched PubMed, Cochrane Database of Systematic Reviews, and the websites of the United States Food and Drug Administration (FDA) and European Medicines Agency for relevant reports published up to March 26, 2016 and reviewed the reference lists from these documents. Search terms included: “varenicline”, “bupropion”, “nicotine replacement therapy”, “safety”, “adverse events”, and “suicide”. Case reports and analyses of post-marketing pharmacovigilance data from Europe, the United States, and other countries detected a possible signal that varenicline use might be associated with neuropsychiatric adverse events, a concern that was eventually extended to use of bupropion. As a result, the FDA issued a post-marketing requirement to the makers of varenicline and bupropion to conduct a randomised controlled trial (RCT) to assess the risk of serious neuropsychiatric adverse events.

In contrast, studies by various authors using a variety of control groups, in a broad range of study populations—some with very large sample sizes—have failed to detect any statistically significant increase in neuropsychiatric adverse events in smokers prescribed varenicline or bupropion compared with nicotine replacement therapy or placebo. While the results of these controlled studies consistently showed varenicline and bupropion to be associated with no greater incidence of serious neuropsychiatric adverse events than active or placebo comparators, some of the studies excluded smokers with psychiatric illness, a group who smokes a large proportion of the cigarettes consumed worldwide, and who may be more vulnerable to neuropsychiatric adverse events.

From the smoking cessation efficacy perspective, most data on the comparative efficacy of varenicline versus nicotine replacement therapy—such as those summarised in Cochrane network meta-analyses finding varenicline superior to single formulation nicotine replacement therapy—rely on indirect comparisons. A recent open-label trial comparing varenicline with single formulation and combination nicotine replacement therapy failed to

detect significant differences across the treatments at 26 weeks. No previous studies have compared the smoking cessation efficacy of the three first-line smoking cessation aids head-to-head in smokers, and none have done so in smokers with current or past psychiatric disorders.

Added value of this study

This study addresses the urgent need for a prospective study of adequate size and rigour to assess the potential for varenicline and bupropion to cause serious neuropsychiatric adverse events. The findings indicate that it is highly unlikely that varenicline and bupropion contribute to neuropsychiatric adverse events of moderate to severe intensity at a rate above 1·5% in smokers without a psychiatric disorder and above 4% in smokers with such disorders. The results are also consistent with no increase in the incidence of these events. The study also provides the first definitive evidence on the relative effectiveness of the different smoking cessation medications in the special population of smokers with psychiatric disorders. The fact that the odds ratios for efficacy did not differ as a function of psychiatric status is critical new information when it comes to treating this population who smoke at rates 2–3 times that of the general population and who are disproportionately affected by smoking-related illness. The findings will be used by medicines regulators, clinicians, and smokers to make an informed choice about life-preserving treatments.

Implications of all the available evidence

The findings from this study, the largest of its kind ever conducted, together with those from meta-analyses of previous RCTs and very large observational cohort studies, make it highly unlikely that varenicline or bupropion increase the risk of moderate to severe neuropsychiatric adverse events in smokers without psychiatric disorders. The evidence from all available sources is less clear in smokers with psychiatric disorders; however, if there is an increased risk in this group, this is expected to be small.

The available evidence, substantially boosted by this study, clearly demonstrates the efficacy of all three first-line smoking cessation medications with varenicline having the largest effect, in smokers with and without psychiatric disorders.

Introduction

The prescription medications, varenicline and bupropion, have been found in multiple randomised trials and real-world observational studies to substantially improve smokers' chances of stopping long term.[1] However, significant concerns have been raised about their safety, particularly with regard to neuropsychiatric adverse events such as suicidality and aggression.[2] Meta-analyses of randomised trials and large comparative observational studies have not supported these safety concerns, but prior to that information becoming available the United States Food and Drug Administration (FDA) required the makers of these medications to conduct a sufficiently large randomised trial to provide greater clarity on their potential safety risks.[3] In addition, the smoking cessation efficacy of these medications relative to each other and to nicotine replacement therapy, especially in smokers with psychiatric disorders, remains uncertain, depending largely on indirect comparisons and a limited number of studies with relatively small sample sizes.[4] The present study sought to address these issues with a very large double-blind, triple-dummy, active- and placebo-controlled, randomised trial in smokers with and without a psychiatric disorder. The issue is of critical importance because of the urgency surrounding smoking cessation, particularly for smokers with respiratory, cardiovascular, or other smoking-related diseases, and the need to be able to provide maximum support for smokers to help them achieve abstinence based on an accurate risk–benefit analysis.

Clinical practice guidelines recommend that the most effective way for moderate to heavy smokers to quit is by combining a smoking cessation medication with counselling.[4] However, smoking cessation support is underutilised,[5] in part due to smokers' and clinicians' concerns that the medications may not be safe, especially regarding the risk of developing serious neuropsychiatric symptoms—a concern that is reflected in the package insert for two of the first-line agents, varenicline and bupropion, as warnings and/or precautions in most countries and as boxed warnings in some countries including the United States. Given the

high risk of smoking-induced illness and death, the reluctance of clinicians to prescribe the most effective smoking cessation medications places many smokers at further risk. Concerns about neuropsychiatric safety of varenicline and bupropion arose from case reports,[6,7] post-marketing surveillance analyses,[2,8] and the initial dearth of studies in smokers with psychiatric disorders who are most likely to report such events.[9] However, studies with active and placebo comparators published over the past 4 years report that use of these medications did not increase neuropsychiatric symptom risk. Randomised, placebo-controlled trials (RCTs) of varenicline in smokers with various psychiatric disorders[10,11] identified no neuropsychiatric safety signals and no worsening of the underlying psychiatric condition. Independent meta-analyses of these RCTs have reported no evidence of an association between varenicline[12,13] or bupropion[14] and neuropsychiatric adverse events. Observational studies examining severe outcomes (e.g., suicidal behaviour, hospitalisations) in large cohorts of smokers, many of whom had comorbid psychiatric disorders, have not found a heightened risk of serious neuropsychiatric adverse events for varenicline[9,15] or bupropion.[16] These studies all have limitations,[3] however. For example, most studies included in the meta-analyses did not prospectively and systematically probe for all serious neuropsychiatric adverse events of interest, and the more recent observational studies might suffer from channelling bias where sicker patients were shunted away from using the non-nicotine smoking cessation aids because of concerns regarding their side effects.[3] Thus, there remains a need to determine the neuropsychiatric safety profile of varenicline and bupropion in a randomised, double-blind, active- and placebo-controlled trial in smokers with and without psychiatric disorders that systematically probes for these neuropsychiatric adverse events while participants are on- and off-treatment during and following their smoking cessation attempt.

In addition to safety issues, the smoking cessation efficacy of the non-nicotine medications relative to nicotine replacement therapy, which also plays a role in determining their benefit–risk ratio, has also not been well studied in head-to-head trials, particularly in smokers with psychiatric disorders. A network meta-analysis conducted by the independent Cochrane

Database Systematic Reviews recommended that direct comparisons among single and combination formulations of nicotine replacement therapy with varenicline would be valuable.[1] A recent open-label trial in lighter smokers[17] further highlights the need for double-blind, placebo-controlled, head-to-head comparisons as evidenced by that study's results being inconsistent with previous findings of meta-analyses that varenicline was more efficacious than single formulation nicotine replacement therapy.[1] It is also not known whether the relative efficacies of these first-line smoking cessation medications differ as a function of a smoker's psychiatric history, because no prior comparative efficacy trials directly compared the medications in smokers with and without psychiatric disorders.

With these gaps in the literature in mind, herein we describe the results of the largest trial of pharmacotherapy for smoking cessation conducted to date, with the objective of comparing the relative safety and efficacy of these medications in smokers with and without psychiatric disorders. The study was requested by, and designed in consultation with, the FDA. The study is also a post-authorisation safety study in the European Union.

Methods

Study design and oversight

The Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) was a multinational, multicentre, randomised, double-blind, placebo- and active-controlled trial, conducted between November 2011 and January 2015, at 140 centres in 16 countries across five continents (Table 1A - Appendix). The trial was registered at ClinicalTrials.gov (identifier: NCT01456936; https://clinicaltrials.gov). Study sites included clinical trial centres, academic centres, and outpatient clinics treating patients with and/or without psychiatric disorders. Written consent forms and study procedures were approved by the institutional review boards or ethics committees at participating institutions. The study adhered to the Declaration of Helsinki[18] and the International Conference on Harmonisation Good Clinical

Practice Guidelines.[19] An independent Data Monitoring Committee reviewed safety data at pre-specified time points to ensure participant safety and sample size adequacy.

Participants

Eligible participants were smokers, aged 18–75 years, with and without pre-specified psychiatric diagnoses per the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)*,[20] who smoked an average of ≥10 cigarettes per day during the prior year, had an exhaled carbon monoxide >10 parts per million at screening, and who were motivated to stop smoking as evidenced by signing the informed consent prior to trial enrollment specifying that a target quit date would be set. Potential participants were recruited from the investigators' own clinics; through newspaper, radio, and television advertising; and fliers and posters. Participants were included in the psychiatric cohort if they met DSM-IV-TR diagnostic criteria for mood disorders including major depressive disorder or bipolar disorder; anxiety disorders including panic disorder, with or without agoraphobia, post-traumatic stress disorder, obsessive-compulsive disorder, social phobia, and generalised anxiety disorder; psychotic disorders including schizophrenia and schizoaffective disorders; or borderline personality disorder. Those with qualifying primary psychiatric disorders were not excluded for other psychiatric co-morbidities, but those secondary allowable diagnoses were also pre-specified and excluded destabilising psychiatric conditions such as alcohol and other drug use disorders within the previous 12 months. Participants had to be considered clinically stable for inclusion (i.e., no exacerbations of their condition in the preceding 6 months; on stable treatment for at least 3 months, with no treatment change anticipated during the study), and considered by the investigator not to be at high risk of self-injury or suicidal behaviour as gauged by participants' responses on the Suicide Behaviors Questionnaire – Revised,[21] or Columbia Suicide Severity Rating Scale (C-SSRS),[22] both administered at screening, and, if necessary, professional mental health evaluation. Participants in the non-psychiatric cohort had no confirmed history of DSM-IV-TR Axis I or II disorders. Complete inclusion/exclusion

criteria are described in Table 2A - Appendix. All participants signed informed consent and received financial compensation for study participation time and travel expenses as per standards set at each trial site.

Randomisation, masking, and study treatment

Eligible participants were stratified 1) into non-psychiatric cohort and four sub-cohorts in the psychiatric cohort based on their psychiatric primary diagnosis, and 2) by site region based on four pre-specified geographic groups (see Table 1). Within this stratification, participants were then randomised to receive maximal target dosages of varenicline 1 mg twice daily, bupropion sustained release 150 mg twice daily, transdermal nicotine patch 21 mg per day with taper, or placebo in a 1:1:1:1 ratio in a triple-dummy design for a 12-week treatment phase followed by a 12-week non-treatment phase (see Figure 1A - Appendix). Participants were asked to complete up to 15 face-to-face visits and 11 telephone visits during the 24-week trial. The triple-dummy design feature required participants to take study medications as blinded tablets dispensed in separate “varenicline” and “bupropion” pill bottles each with matching placebo along with either applying active or placebo patches on a daily basis. Thus, all participants received active treatment or placebo for each of the three medication conditions and were instructed to use all three of the treatments each day during active treatment phase. Overall enrolment was to be equal (N=4000; 1000 per treatment arm) for the two cohorts. Treatment groups were balanced across the five diagnostic groups (non-psychiatric cohort, psychiatric cohort mood, psychiatric cohort anxiety, psychiatric cohort psychotic, and psychiatric cohort personality disorders) for each of the four regions. A randomisation administrator, independent from the clinical study team, prepared the computer-generated randomisation schedule used to assign participants to treatment using a block size of 8 and 1:1:1:1 ratio for each of the twenty “diagnosis by region” combinations. Investigators obtained participant identification numbers via a web-based or telephone call-in drug management system. Study product kit codes did not allow deciphering of randomised

treatment or block size. As such, participants, investigators, and research personnel were blinded to treatment assignments.

Participants set a target quit date 1 week after randomisation to coincide with the end of the titration for varenicline and bupropion and the initiation of nicotine patch treatment. Smoking cessation counselling of ≤10 minutes based on Agency for Healthcare Research and Quality guidelines[4] was given at each clinic visit. Participants were encouraged to complete all study visits even if treatment was discontinued.

At each study visit, pill and patch counts were performed and documented to measure medication compliance. Compliance was defined as having any (partial or full) daily dose of study drug for 80% of the planned treatment period (i.e., a minimum of 68 days). Using this metric, overall treatment compliance was ~80% across the four treatment conditions.

Outcomes

Safety

The primary endpoint was a composite measure based on post-marketing reports of neuropsychiatric adverse events in smokers taking varenicline and bupropion. It comprised 16 neuropsychiatric symptom categories that included 261 Medical Dictionary for Regulatory Activities version 18.0 (MedDRA, v.18.0)–derived preferred terms. The primary endpoint captured all volunteered, observed, and solicited neuropsychiatric adverse events (new events or increases in severity of ongoing symptoms) in these 16 components, regardless of whether the site study physician assessed them to be causally related to study medications. The primary endpoint was met when participants reported ≥1 event coding to any of the 261 MedDRA-derived preferred terms across the 16 symptom categories during treatment or within 30 days of treatment discontinuation that met pre-established severity criteria. Adverse events were rated by trained investigators as “mild” (no interference with subject’s usual daily functioning), “moderate” (some interference with functioning), or “severe” (significant interference). Pre-specified severity criteria for the primary neuropsychiatric adverse event endpoint required adverse events for the four components expected to be

reported more commonly (anxiety, depression, feeling abnormal, or hostility) to be rated as severe. Neuropsychiatric adverse events in the remaining 12 categories (agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, behaviour, or completed suicide) met severity criteria when rated as either moderate or severe. A simplified scheme of the primary composite safety endpoint is illustrated in Table 3A - Appendix.

Secondary safety endpoints included the subset of all neuropsychiatric adverse events that were rated severe and the occurrence of each of the individual components. Other safety evaluations included psychiatric rating scales (see below), all adverse events, vital signs, and select laboratory values. Cardiovascular safety data will be reported separately, after completion of the 28-weeks post-treatment extension phase.

Efficacy

The primary efficacy endpoint for smoking cessation was the continuous abstinence rate for weeks 9–12. Participants were considered abstinent who self-reported tobacco abstinence throughout the period in conjunction with no exhaled carbon monoxide level >10 parts per million. Missing self-reports prior to week 12 were imputed via a backward carry method (missing at week 12 was deemed a smoker). Missing carbon monoxide measurements were imputed as <10 parts per million, but a sensitivity analysis was also conducted imputing missing values as smoking. In accordance with recommended practice,[23] participants who were lost to follow-up were considered to be smokers. The pre-designated secondary efficacy endpoint was carbon monoxide-confirmed continuous abstinence for weeks 9–24 defined similarly. 7-day-point-prevalence of abstinence at all visits/contacts was also a pre-specified outcome.

Assessments

Tobacco and nicotine use were assessed with a structured questionnaire at all clinic visits and telephone contacts. All clinic visits included expired air carbon monoxide measurement.

Emergence of adverse events was assessed with open-ended questions, direct observation, and a semi-structured Neuropsychiatric Adverse Events Interview (NAEI) performed at all study visits by trained interviewers to fully capture neuropsychiatric adverse events of interest (see Table 4A - Appendix). The NAEI comprises 25 questions to probe for psychiatric symptoms during a clinical trial;[10] positive responses were considered possible neuropsychiatric adverse events that were evaluated further by the trained interviewer by inquiring about each symptom's frequency, duration, and severity. General or psychiatric adverse events that met FDA requirements for serious adverse events—e.g., resulting in death, hospitalisation, significant disability, or life-threatening events—were classified accordingly. In addition, investigators were instructed to evaluate whether positive responses on the C-SSRS,[22] as well as any proxy reports, such as from participants' family members or physicians, were neuropsychiatric adverse events.

Psychiatric diagnosis was assessed at screening with the Structured Clinical Interviews for DSM-IV-TR Axis I & II Disorders (SCID-I & -II).[24,25] Aspects of psychiatric symptom severity were assessed at baseline and all visits with the C-SSRS,[22] and Hospital Anxiety and Depression Scale (HADS).[26] Participants who reported a severe neuropsychiatric adverse event, were considered to be at increased suicide risk, or had any significant worsening of their psychiatric condition, underwent a psychiatric evaluation/risk assessment at that visit by a mental health professional who made specific treatment/intervention recommendations, including whether the participant could continue the study. The Fagerström Test for Cigarette Dependence (FTCD)[27] was used to assess cigarette dependence severity at baseline.

Statistical analysis

The sample for this study was driven by requirement to estimate the magnitude of increase in the rate of neuropsychiatric adverse events relative to placebo group with a pre-specified level of precision. Based on pooled data from previous RCTs,[28] the underlying placebo rates for neuropsychiatric adverse events in the non-psychiatric cohort and psychiatric cohort were

postulated to be 3·5% and 7·0%, respectively. A sample size of 2000 per treatment group was determined to be sufficient to estimate a 75% increase in neuropsychiatric adverse event rate within ±1·59%. The sample size is also sufficient to detect a two-fold increase in the odds of abstinence rate in the placebo group.

Point and interval estimates of risk differences (RDs) - that is, differences in percentages of incidence of neuropsychiatric adverse events, were obtained using generalized linear regression with terms to account for treatment, cohort (non-psychiatric cohort and psychiatric cohort), region (reduced to two regions: United States and non-United States), and interactions. Differences were considered significant if their associated 95% confidence intervals (CIs) were entirely below or above 0. Logistic regression analysis was used for the analysis of abstinence endpoints. The estimates of odds ratios (ORs) and corresponding 95% CIs were obtained via linear contrasts.

All participants randomised to study medications comprised the population for efficacy analyses and participants treated with study medications comprised the population for analysis of safety. The varenicline and bupropion comparisons versus placebo were pre-specified as primary; all other treatment comparisons were deemed secondary. No adjustments for multiplicity of testing were made.

Role of the funding source

The study is a post-marketing requirement in the United States for Pfizer and GlaxoSmithKline. As such, the study was designed by sponsor-employees (with input from A Krishen, and Drs. L St. Aubin, D Lawrence, and C Russ) and academic authors (Dr. RM Anthenelli, and also with input from Drs. NL Benowitz, AE Evins, and R West). The lead academic (corresponding) author prepared the initial draft of the manuscript. All authors were involved with the acquisition, analysis, or interpretation of the data and critically revised the manuscript for important intellectual content. The lead academic author had full access to all data in the study and had final responsibility for the decision to submit for publication. Professional editorial assistance for all drafts was provided by Engage Scientific and was

funded by Pfizer. All authors assume responsibility for the completeness and integrity of the data and for the fidelity of the study to the protocol and statistical analysis plan.

Results

Participants

As depicted in Figure 1, of 11186 smokers screened, 8144 (72·8%) were randomised; 4028 to the non-psychiatric cohort and 4116 to the psychiatric cohort. Among treated participants in the non-psychiatric cohort and psychiatric cohort, 3145 (78·9%) and 3023 (74·2%), respectively, completed treatment, and 3124 (78·4%) and 3169 (77·8%) participants, respectively, completed the study. Reasons for discontinuations were similar across cohorts and treatment groups.

Baseline demographic, smoking, and psychiatric characteristics for all treated participants are presented in Table 1. Overall the study population included 3549 (44%) men, had an average age of 46·5 years, and 6584 (82%) participants of white race/ethnicity. Most participants came from the United States (4207 [52%]). Participants smoked an average of 21 cigarettes per day with an average FTCD of 5·8 and 6647 (82%) participants had made at least one prior quit attempt. The treatment groups had similar baseline characteristics within cohorts, but smokers in the psychiatric cohort were more likely to be female, reside in the US, and have higher FTCD scores. Smokers in the psychiatric cohort met DSM-IV-TR criteria for primary mood (2882 [70·7%] participants), anxiety (782 [19·2%] participants), psychotic (386 [9·5%] participants), and borderline personality disorders (24 [0·6%] participants), and 1996 (49·0%) participants were taking psychotropic medications at baseline. In the psychiatric cohort, 34% (1377 participants) had a history of suicidal ideation and 13% (514 participants) of suicidal behaviour based on the C-SSRS.

Primary safety endpoint

The overall incidence of the neuropsychiatric adverse event endpoint was similar across the four treatment groups: varenicline 4·0% (80/2016 participants), bupropion 4·5% (90/2006 participants), NRT 3·9% (78/2022 participants), and placebo 3·7% (74/2014 participants). As seen in Table 2, there were more neuropsychiatric adverse events in the psychiatric cohort than the non-psychiatric cohort ($p<0·0001$ for the cohort effect). There was a treatment by cohort interaction ($p=0·0652$), so analyses of neuropsychiatric adverse events by treatment assignment are presented for each cohort separately in Table 2. For the non-psychiatric cohort, the risk for the composite safety endpoint was lower for participants assigned to varenicline than those assigned to placebo (RD, −1·28; 95% CI −2·40 to −0·15), while there was no significant difference in neuropsychiatric adverse events in those assigned to bupropion versus placebo. Differences between varenicline and nicotine patch and between bupropion and nicotine patch were also not significant in the non-psychiatric cohort. In the psychiatric cohort, there were no significant pair-wise treatment differences (95% CIs included 0).

A third or fewer of the participants (between 2–5 per treatment arm in the non-psychiatric cohort and 10–17 in the psychiatric cohort) who met the primary safety endpoint reported more than one neuropsychiatric adverse event (see Table 5A - Appendix).

Secondary safety endpoints

As shown in Table 2, of the participants reporting the primary neuropsychiatric endpoint, the percentage of those reporting neuropsychiatric adverse events that were severe, met serious adverse event criteria, or led to treatment discontinuations or interventions (i.e., the clinically most significant events), was lower in the non-psychiatric cohort than the psychiatric cohort and was similar across treatment groups.

The number of participants reporting suicidal ideation and/or behaviour on the C-SSRS was greater in the psychiatric cohort than in the non-psychiatric cohort and similar across treatment arms (Table 3). There was one completed suicide in the study in a placebo-treated participant in the non-psychiatric cohort.

The average total HADS score improved from baseline through the treatment phase by approximately 2 points in the non-psychiatric cohort and 3 points in the psychiatric cohort, an effect that was similar across the treatment groups (see Figure 2A - Appendix).

Table 4 lists all adverse events (mild, moderate, and severe) in the Psychiatric Disorder MedDRA category occurring in ≥1% of any treatment group in either cohort, regardless of whether they met the criteria for the primary neuropsychiatric adverse event endpoint. Those in the psychiatric cohort were more likely to report neuropsychiatric adverse events of all types than those in the non-psychiatric cohort. The profile of adverse events exhibited (e.g., abnormal dreams more common for varenicline and nicotine patch compared with placebo) was consistent with previous reports. Table 6A - Appendix summarises incidences for general adverse events, serious adverse events, deaths, treatment discontinuations, and adverse events observed in ≥5% of participants. Overall, the treatments were well tolerated.

Primary efficacy endpoint

As specified in the study protocol, an analysis was undertaken to assess whether treatment efficacy varied between non-psychiatric cohort and psychiatric cohort, and while the abstinence rates are lower in the psychiatric cohort versus non-psychiatric cohort (see Figure 2), no evidence was found for an interaction (p=0·6237). The continuous abstinence rates for weeks 9–12 and 9–24 by treatment and the ORs for all pair-wise comparisons are presented for the combined sample as well as for the two cohorts in Figure 2. Varenicline showed superior efficacy to placebo and to both nicotine patch and bupropion at end of treatment (weeks 9–12) and follow up (weeks 9–24). Bupropion showed similar efficacy to nicotine patch and both showed superior efficacy versus placebo. Imputing missing carbon monoxide measurements that occurred in 72 participants self-reporting continuous abstinence during weeks 9–24 as smoking did not significantly affect the results (see Table 7A - Appendix). Figure 3A - Appendix shows the 7-day point prevalence of abstinence for weeks 1–24, and yields results consistent with the continuous abstinence rates.

Discussion

This large multinational trial did not detect a significant increase in rates of moderate to severe neuropsychiatric adverse events with either varenicline or bupropion relative to nicotine patch or placebo in those with or without psychiatric disorders. Neither did it find treatment-associated changes on validated, longitudinal assessments of suicidality using the C-SSRS, of mood and anxiety symptoms with the HADS, or conventional assessments of neuropsychiatric adverse events including treatment discontinuation. Varenicline demonstrated superior efficacy to bupropion and nicotine patch in both cohorts, while bupropion exhibited similar efficacy to nicotine patch with both showing superior efficacy to placebo in both cohorts.

Interpreting the confidence intervals for the primary outcome measure, the findings make it highly unlikely that varenicline or bupropion increase moderate to severe neuropsychiatric adverse events by more than 1·5 percentage point in smokers without psychiatric disorders, and by 4 percentage points in smokers with psychiatric disorders. They are also consistent with there being no increase in neuropsychiatric adverse events in either population of smokers.

The study detected an approximate 4 percentage point significant difference in the rate of neuropsychiatric adverse events between the psychiatric and non-psychiatric cohorts. Moreover, the observed incidence was close to the postulated values—approximately 2% in the non-psychiatric cohort and 6% in the psychiatric cohort—so it seems unlikely that failure to detect medication effects was attributable to lack of sensitivity of the measures or selection of smokers with unusually good mental health.

These findings add substantially to those of the previous RCT meta-analyses[12-14] and observational studies,[9,15,16,29] using a rigorous experimental design and very detailed proactive assessment of treatment-emergent and post-treatment neuropsychiatric symptoms, thereby addressing limitations of the previous studies. They therefore provide

important new information on which regulators, prescribers, and smokers can make an informed choice when deciding how best to address nicotine dependence.

The findings demonstrate for the first time that the efficacy of the medications in terms of ORs is similar for smokers with or without psychiatric disorders. Smokers in the psychiatric cohort achieved lower abstinence rates than those in the non-psychiatric cohort, so the absolute effect size was smaller in those with psychiatric disorders than those without, but it was still substantial. Moreover, inspection of the 7-day point prevalence of abstinence curves reveals a similar 'recruitment to abstinence' phenomenon previously described in non-psychiatrically ill smokers with varenicline. Further analyses will be helpful in assessing whether there is any evidence of differential effectiveness as a function of the severity of the psychiatric disorder or diagnostic category.

This study provides the first evidence of comparative efficacy between the three main pharmacological treatments to aid smoking cessation in a double-blind and triple-dummy trial. The size of the differences is similar to what was predicted from the Cochrane network meta-analysis.[1] The fact that this study was conducted in multiple centres in countries with widely different attitudes regarding tobacco use, confirms the generalisability of these conclusions across cultures.

Our results appear to differ from a recent open-label study that compared varenicline with combination nicotine replacement therapy (nicotine patch + lozenge) and single formulation nicotine replacement therapy (nicotine patch).[17] On the most comparable outcome measure of prolonged abstinence at 26 weeks, that study found an OR of 1·1, but with a relatively small sample size, the 95% CIs (0·7 to 1·7) overlapped with the point estimate found in the present study (1·52) and with the estimate from the Cochrane network meta-analysis (1·57).

The present study had several limitations. First, we included smokers with psychiatric disorders who were stable and treated or who had prior psychiatric conditions (e.g., major depressive disorder) that were in remission. Thus, these selection effects might have influenced the findings, and our results may not generalise to those with untreated or symptomatically unstable psychiatric illness. In a similar vein, we limited the scope of the

psychiatric cohort to smokers in four major disease categories—mood, anxiety, psychotic, and borderline personality disorders—and excluded participants with other current substance use disorders or who were at imminent risk for suicide, further limiting generalisability. Second, the 24-week duration of the study and frequent monitoring may not mirror a 'real world' smoking cessation attempt. Third, although this is the largest double-blind, placebo-controlled safety and efficacy trial of pharmacotherapy for smoking cessation conducted to date, some of the sub-cohorts in the psychiatric cohort are smaller than others, our study was not powered to detect differences in rare events such as completed suicides, nor can we rule out, based on the upper bound 95% CIs, an increase of serious neuropsychiatric adverse events as defined of up to 4% in the psychiatric cohort. Fourth, we recruited individuals who smoked, on average, at least 10 cigarettes per day and who were moderately nicotine dependent. Thus, our findings might not generalise to lighter, less severely dependent smokers. Fifth, our analyses did not consider the potential moderating effects of sex, dependence severity, and depression/anxiety symptoms between the cohorts, which were not pre-specified in our statistical analysis plan, but will be considered along with other predictor variables in subsequent manuscripts. Finally, attrition occurred across all treatment groups between both cohorts, and missing data could have affected outcomes. These limitations aside, the lack of any signal for serious neuropsychiatric adverse events in this and other RCTs,[10-14,30] combined with the growing number of studies finding no such association in large cohorts of smokers with or without psychiatric disorders,[9,15,16,29] makes it improbable that use of these medications in psychiatrically stable smokers is causally associated with a heightened neuropsychiatric safety risk.

In summary, in the context of evidence from clinical trials and observational cohort studies, this large, multinational trial provides further evidence that varenicline and bupropion can be used safely by psychiatrically stable smokers. While varenicline appears to be the most effective single pharmacotherapy available, all of the first-line medications—varenicline, bupropion, and nicotine patch—are efficacious compared with placebo.

Contributors

RMA and DL had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. RMA, LSA, NLB, AEE, AK, DL, CR, and RW had input to study design. DL and AK conducted the statistical analyses. LSA, DL, and TM were involved in study supervision. All authors were involved in acquisition, analysis, or interpretation of data. RMA drafted the manuscript and all authors were involved in the critical revision of the manuscript for important intellectual content.

Declaration of Interests

RMA reports receiving grants from Pfizer and Alkermes, and providing consulting and/or advisory board services to Pfizer, Arena Pharmaceuticals, and Cerecor. RMA's writing of this manuscript was supported, in part, by National Institute on Alcohol Abuse and Alcoholism Grant #s U01 AA013641 and R01 AA019720; National Institute on Drug Abuse/Veterans Affairs Cooperative Studies #s 1031 and 1032; and Veterans Affairs Merit Award # NEUA-003-08S. NLB reports providing consulting and/or advisory board services to Pfizer and GlaxoSmithKline, and having been a paid expert witness in litigation against tobacco companies. RW reports receiving grants from Pfizer, Johnson & Johnson, and GlaxoSmithKline, and receiving personal fees for advisory board services from Pfizer and GlaxoSmithKline. RW's salary is funded by Cancer Research United Kingdom. AEE reports receiving grants from Pfizer and Forum Pharmaceuticals, and receiving personal fees for advisory board services from Pfizer and Reckitt Benckizer. AEE's writing of the manuscript was supported by a National Institute on Drug Abuse Career Award in Patient-Oriented Research, K24 DA030443. LSA, TM, DL, and CR are employees and stockholders of Pfizer. JA is an employee of GlaxoSmithKline and stockholder of that company. AK is a PAREXEL employee working on behalf of GlaxoSmithKline. The opinions expressed in this article are the authors own, and do not necessarily reflect the views of their employers. Parts of this paper were presented as abstracts and a poster at the 22nd Annual Meeting of the Society for Research on Nicotine and Tobacco, Chicago, Illinois, March 2016.

Acknowledgements

We thank the investigators and study site personnel involved in the study. They or their institutions were compensated for their contributions by Pfizer and GlaxoSmithKline. Editorial support (in the form of creating tables and figures, formatting references, collating review comments, and proofing and formatting for submission) was provided by Anne Jakobsen, MSc and Abegale Templar, PhD (both Engage Scientific, Horsham, United Kingdom) and funded by Pfizer.

References

1. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev* 2013; **5**: CD009329.

2. Institute for Safe Medication Practices. Quarter Watch: Monitoring FDA MedWatch Reports. September 24, 2014 — Data from 2013 Quarters 2 & 3. 2014. http://www.ismp.org/quarterwatch/pdfs/2013Q3.pdf (accessed Sept 8, 2015e).

3. Food and Drug Administration Briefing Document. Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, October 16, 2014, Chantix and Serious Neuropsychiatric Adverse Events. 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM418705 (accessed Sept 9, 2015e).

4. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008. U.S. Department of Health and Human Services, Public Health Service. www.surgeongeneral.gov/initiatives/tobacco/index.html. (accessed Sept 30, 2015e).

5. Smith AL, Carter SM, Chapman S, Dunlop SM, Freeman B. Why do smokers try to quit without medication or counselling? A qualitative study with ex-smokers. *BMJ Open* 2015; **5**: e007301.

6. Freedman R. Exacerbation of schizophrenia by varenicline. *Am J Psychiatry* 2007; **164**: 1269.

7. Yousefi MK, Folsom TD, Fatemi SH. A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. *J Addict Res Ther* 2011; **S4**.

8. US Food and Drug Administration. FDA Drug Safety Newsletter - Volume 2, Number 1, 2009. 2009. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107311.htm (accessed Sept 8, 2015e).

9. Pasternak B, Svanström H, Hviid A. Use of varenicline versus bupropion and risk of psychiatric adverse events. *Addiction* 2013; **108**: 1336-43.

10. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med* 2013; **159**: 390-400.

11. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *JAMA* 2014; **311**: 145-54.

12. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. *Am J Psychiatry* 2013; **170**: 1460-7.

13. Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. *BMJ* 2015; **350**: h1109.

14. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2014; **1**: CD000031.

15. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. *BMJ* 2015; **350**: h2388.

16. Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. *BMJ* 2013; **347**: f5704.

17. Baker TB, Piper ME, Stein JH, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. *JAMA* 2016; **315**: 371-9.

18. World Medical Association 2008. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/17c.pdf (accessed Oct 8, 2015e).

19. International Conference on Harmonisation. Guideline For Good Clinical Practice E6(R1). 1996. http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.html (accessed Oct 8, 2015e).

20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revison. 2000. http://dsm.psychiatryonline.org/doi/abs/10.1176/appi.books.9780890420249.dsm-iv-tr (accessed Oct 8, 2015e)

21. Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. *Assessment* 2001; **8**: 443-54.

22. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry* 2011; **168**: 1266-77.

23. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. *Nicotine Tob Res* 2003; **5**: 13-25.

24. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; November 2002.

25. First M, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, D.C.: American Psychiatric Press, Inc.; 1997.

26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983; **67**: 361-70.

27. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. *Nicotine Tob Res* 2012; **14**: 75-8.

28. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. *Drug Saf* 2010; **33**: 289-301.

29. Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. *Lancet Respir Med* 2015; **3**: 761-8.

30. Cinciripini PM, Robinson JD, Karam-Hage M, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. *JAMA Psychiatry* 2013; **70**: 522-33.

[[FIGURE LEGENDS]]

Figure 1: Participant disposition

Figure 2: Continuous abstinence rates for weeks 9–12 and 9–24

Analyses based on the all-randomised population. CI=confidence interval. OR=odds ratio.

[[TABLES & FIGURES]]

Table 1: Baseline characteristics

	Non-psychiatric cohort* (N=3984)				Psychiatric cohort* (N=4074)			
	Varenicline (n=990)	**Bupropion (n=989)**	**Nicotine patch (n=1006)**	**Placebo (n=999)**	**Varenicline (n=1026)**	**Bupropion (n=1017)**	**Nicotine patch (n=1016)**	**Placebo (n=1015)**
Demographic characteristics								
Male	510 (51·5%)	503 (50·9%)	497 (49·4%)	489 (48·9%)	392 (38·2%)	387 (38·1%)	384 (37·8%)	387 (38·1%)
Age, years	45·8 (13·0)	46·0 (13·0)	46·1 (12·8)	45·9 (12·8)	47·2 (11·8)	46·7 (12·2)	47·6 (11·5)	46·9 (11·5)
Race								
White	819 (82·7%)	820 (82·9%)	837 (83·2%)	817 (81·8%)	849 (82·7%)	816 (80·2%)	804 (79·1%)	822 (81·0%)
Black	135 (13·6%)	116 (11·7%)	127 (12·6%)	126 (12·6%)	145 (14·1%)	165 (16·2%)	176 (17·3%)	155 (15·3%)
Asian	14 (1·4%)	16 (1·6%)	13 (1·3%)	19 (1·9%)	5 (0·5%)	10 (1·0%)	11 (1·1%)	7 (0·7%)
Other	22 (2·2%)	37 (3·7%)	29 (2·9%)	37 (3·7%)	27 (2·6%)	26 (2·6%)	25 (2·5%)	30 (3·0%)
Unspecified	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)
Weight, kg	80·0 (19·5)	80·4 (20·1)	81·6 (19·6)	80·6 (19·3)	83·0 (21·5)	82·5 (21·3)	80·8 (20·1)	82·7 (21·3)
Region								
United States	464 (46·9%)	466 (47·1%)	476 (47·3%)	469 (46·9%)	590 (57·5%)	586 (57·6%)	575 (56·6%)	581 (57·2%)
Western Europe + other countries†	322 (32·5%)	320 (32·4%)	322 (32·0%)	326 (32·6%)	297 (28·9%)	292 (28·7%)	303 (29·8%)	297 (29·3%)
Eastern Europe‡	111 (11·2%)	112 (11·3%)	112 (11·1%)	111 (11·1%)	94 (9·2%)	92 (9·0%)	93 (9·2%)	93 (9·2%)

South and Middle America§	93 (9·4%)	91 (9·2%)	96 (9·5%)	93 (9·3%)	45 (4·4%)	47 (4·6%)	45 (4·4%)	44 (4·3%)
Smoking characteristics								
FTCD score	5·5 (2·0)	5·5 (2·0)	5·6 (2·0)	5·5 (2·0)	6·0 (1·9)	6·1 (1·9)	6·0 (2·0)	5·9 (2·0)
Duration of smoking, years	27·8 (12·8)	28·2 (13·0)	28·2 (12·8)	28·2 (12·6)	28·9 (11·8)	28·2 (12·4)	28·9 (11·9)	28·3 (11·6)
Cigarettes per day in past month, n	20·8 (8·3)	20·6 (7·8)	20·8 (8·2)	20·5 (7·9)	20·6 (8·0)	20·5 (8·2)	20·8 (9·1)	20·7 (8·2)
Previous quit attempts, n	3·3 (13·8)	3·4 (10·3)	3·1 (4·2)	3·2 (7·4)	3·4 (7·7)	3·5 (6·9)	3·3 (5·3)	3·6 (10·9)
Participants with ≥1 previous quit attempts	809 (81·7%)	808 (81·7%)	832 (82·7%)	795 (79·6%)	855 (83·3%)	843 (82·9%)	851 (83·8%)	854 (84·1%)
Psychiatric characteristics								
Primary diagnosis, SCID								
Unipolar and bipolar mood disorders	Not applicable	Not applicable	Not applicable	Not applicable	731 (71·2%)	716 (70·4%)	713 (70·2%)	722 (71·1%)
Anxiety disorders	Not applicable	Not applicable	Not applicable	Not applicable	193 (18·8%)	200 (19·7%)	195 (19·2%)	194 (19·1%)
Psychotic disorders	Not applicable	Not applicable	Not applicable	Not applicable	95 (9·3%)	96 (9·4%)	99 (9·7%)	96 (9·5%)
Personality disorders	Not applicable	Not applicable	Not applicable	Not applicable	7 (0·7%)	5 (0·5%)	9 (0·9%)	3 (0·3%)
HADS								
Total score	4·4 (4·4) [0–28]	4·1 (4·1) [0–24]	4·2 (4·1) [0–25]	4·5 (4·3) [0–22]	8·3 (6·5) [0–30]	8·7 (6·9) [0–36]	8·4 (6·6) [0–31]	8·2 (6·2) [0–36]
Anxiety subscale score	2·8 (2·8)	2·7 (2·6)	2·7 (2·6)	2·9 (2·8)	5·1 (3·8)	5·3 (4·0)	5·2 (4·0)	5·2 (3·8)
Depression subscale score	1·6 (2·1)	1·4 (2·0)	1·5 (2·0)	1·6 (2·1)	3·2 (3·3)	3·4 (3·5)	3·2 (3·3)	3·1 (3·2)
Lifetime suicide-related history from C-SSRS								

Ideation	48 (4·8%)	43 (4·3%)	50 (5·0%)	49 (4·9%)	338 (32·9%)	357 (35·1%)	333 (32·8%)	349 (34·4%)
Behaviour	6 (0·6%)	9 (0·9%)	7 (0·7%)	6 (0·6%)	137 (13·4%)	143 (14·1%)	111 (10·9%)	123 (12·1%)
Receiving psychotropic medication at enrolment	75 (7.6%)	72 (7.3%)	85 (8.4%)	96 (9.6%)	534 (52.0%)	471 (46.3%)	491 (48.3%)	500 (49.3%)
Antidepressants	22 (2·2%)	21 (2·1%)	26 (2·6%)	36 (3·6%)	384 (37·4%)	318 (31·3%)	334 (32·9%)	341 (33·6%)
Anxiolytics, hypnotics, and other sedatives	53 (5·4%)	49 (5·0%)	61 (6·1%)	61 (6·1%)	160 (15·6%)	141 (13·9%)	186 (18·3%)	136 (13·4%)
Antipsychotics	2 (0·2%)	2 (0·2%)	2 (0·2%)	7 (0·7%)	165 (16·1%)	160 (15·7%)	167 (16·4%)	159 (15·7%)
Mood stabilisers	6 (0·6%)	1 (0·1%)	3 (0·3%)	10 (1·0%)	16 (1·6%)	22 (2·2%)	22 (2·2%)	22 (2·2%)
Other¶	1 (0·1%)	2 (0·2%)	3 (0·3%)	0 (0%)	1 (0·1%)	6 (0·6%)	1 (0·1%)	3 (0·3%)

Data are mean (standard deviation) [range] or n (%), unless otherwise stated. C-SSRS=Columbia Suicide Severity Rating Scale. FTCD=Fagerström Test for Cigarette Dependence. HADS=Hospital Anxiety and Depression Scale. SCID=Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Axis I or II Disorders. *All-treated population. †Western Europe and other countries: Australia, Canada, Denmark, Finland, Germany, New Zealand, South Africa, Spain. ‡Eastern Europe: Bulgaria, Russian Federation, Slovakia. §South and Middle America: Argentina, Brazil, Chile, Mexico. ¶"Other" category refers to psychostimulants, amino acids, and herbals/botanicals.

Table 2: Summary of primary neuropsychiatric composite safety endpoint and its components

	Non-psychiatric cohort* (N=3984)				Psychiatric cohort* (N=4074)			
	Varenicline (n=990)	**Bupropion (n=989)**	**Nicotine patch (n=1006)**	**Placebo (n=999)**	**Varenicline (n=1026)**	**Bupropion (n=1017)**	**Nicotine patch (n=1016)**	**Placebo (n=1015)**
Primary composite neuropsychiatric endpoint	13 (1·3%)	22 (2·2%)	25 (2·5%)	24 (2·4%)	67 (6·5%)	68 (6·7%)	53 (5·2%)†	50 (4·9%)
Estimated primary composite neuropsychiatric adverse events, %	1·25 (0·60 to 1·90)	2·44 (1·52 to 3·36)	2·31 (1·37 to 3·25)	2·52 (1·58 to 3·46)	6·42 (4·91 to 7·93)	6·62 (5·09 to 8·15)	5·20 (3·84 to 6·56)	4·83 (3·51 to 6·16)
Difference in risk of composite primary endpoint, RD (% [95% CI])								
vs placebo	−1·28 (−2·40 to −0·15)	−0·08 (−1·37 to 1·21)	−0·21 (−1·54 to 1·12)	Not applicable	1·59 (−0·42 to 3·59)	1·78 (−0·24 to 3·81)	0·37 (−1·53 to 2·26)	Not applicable
vs nicotine patch	−1·07 (−2·21 to 0·08)	0·13 (−1·19 to 1·45)	Not applicable	Not applicable	1·22 (−0·81 to 3·25)	1·42 (−0·63 to 3·46)	Not applicable	Not applicable
vs bupropion	−1·19 (−2·30 to −0·09)	Not applicable	Not applicable	Not applicable	−0·20 (−2·34 to 1·95)	Not applicable	Not applicable	Not applicable
Components of primary neuropsychiatric composite endpoint								
Anxiety‡	0 (0%)	1 (0·1%)	0 (0%)	3 (0·3%)	5 (0·5%)	4 (0·4%)	6 (0·6%)	2 (0·2%)
Depression‡	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	6 (0·6%)	4 (0·4%)	7 (0·7%)	6 (0·6%)

Feeling abnormal‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)
Hostility‡	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Agitation§	10 (1·0%)	11 (1·1%)	19 (1·9%)	11 (1·1%)	25 (2·4%)	29 (2·9%)	21 (2·1%)	22 (2·2%)
Aggression§	3 (0·3%)	3 (0·3%)	2 (0·2%)	3 (0·3%)	14 (1·4%)	9 (0·9%)	7 (0·7%)	8 (0·8%)
Delusions§	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	1 (0·1%)	1 (0·1%)	1 (0·1%)	0 (0%)
Hallucinations§	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	5 (0·5%)	4 (0·4%)	2 (0·2%)	2 (0·2%)
Homicidal ideation§	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mania§	0 (0%)	1 (0·1%)	2 (0·2%)	2 (0·2%)	7 (0·7%)	9 (0·9%)	3 (0·3%)	6 (0·6%)
Panic§	0 (0%)	4 (0·4%)	1 (0·1%)	3 (0·3%)	7 (0·7%)	16 (1·6%)	13 (1·3%)	7 (0·7%)
Paranoia§	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	2 (0·2%)
Psychosis§	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	4 (0·4%)	2 (0·2%)	3 (0·3%)	1 (0·1%)
Suicidal behaviour§	0 (0%)	1 (1·0%)	1 (0·1%)	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)	1 (0·1%)
Suicidal ideation§	0 (0%)	1 (0·1%)	2 (0·2%)	3 (0·3%)	5 (0·5%)	2 (0·2%)	3 (0·3%)†	2 (0·2%)
Completed suicide§	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Primary composite neuropsychiatric endpoint (severe intensity only)	1 (0·1%)	4 (0·4%)	3 (0·3%)	5 (0·5%)	14 (1·4%)	14 (1·4%)	14 (1·4%)	13 (1·3%)
Components of primary neuropsychiatric composite endpoint (severe intensity only)								
Anxiety‡	0 (0%)	1 (0·1%)	0 (0%)	3 (0·3%)	5 (0·5%)	4 (0·4%)	6 (0·6%)	2 (0·2%)
Depression‡	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	6 (0·6%)	4 (0·4%)	7 (0·7%)	6 (0·6%)

Feeling abnormal‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)
Hostility‡	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Agitation‡	0 (0%)	0 (0%)	2 (0·2%)	0 (0%)	1 (0·1%)	1 (0·1%)	4 (0·4%)	2 (0·2%)
Aggression‡	1 (1·0%)	1 (0·1%)	0 (0%)	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)	1 (0·1%)
Delusions‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Hallucinations‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)
Homicidal ideation‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mania‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (0·2%)	1 (0·1%)	0 (0%)	0 (0%)
Panic‡	0 (0%)	1 (0·1%)	1 (0·1%)	1 (0·1%)	0 (0%)	1 (0·1%)	0 (0%)	1 (0·1%)
Paranoia‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Psychosis‡	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)
Suicidal behaviour‡	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)	1 (0·1%)
Suicidal ideation‡	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	1 (0·1%)	0 (0%)	1 (0·1%)	0 (0%)
Completed suicide‡	0 (0%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Events in the primary endpoint								
Serious adverse events¶	0 (0%)	1 (0·1%)	2 (0·2%)	3 (0·3%)	6 (0·6%)	5 (0·5%)	3 (0·3%)†	3 (0·3%)
Resulting in permanent treatment discontinuations	1 (0·1%)	5 (0·5%)	7 (0·7%)	3 (0·3%)	16 (1·6%)	15 (1·5%)	12 (1·2%)	15 (1·5%)
Leading to interventions**	0 (0%)	2 (0·2%)	1 (0·1%)	3 (0·3%)	7 (0·7%)	12 (1·2%)	7 (0·7%)	11 (1·1%)
Combined serious adverse events, severe adverse events, and leading	2 (0·2%)	8 (0·8%)	8 (0·8%)	10 (1·0%)	28 (2·7%)	28 (2·8%)	21 (2·1%)†	29 (2·9%)

to treatment discontinuations or interventions (at least one of)

Data are n (%) or mean (95% CI), unless otherwise stated. CI=confidence interval. RD=risk difference. Based on least squares means analysis, point estimate and its 95% CI. Estimated risk difference is based on a General Linear Model with terms treatment, cohort, region, and treatment by cohort interaction. Region uses 2-level classification (United States, non-United States). Adverse events reported during treatment and ≤30 days after last dose. Subjects are counted only once per each row, even if they have reported multiple events; subjects can be counted in multiple rows. *All-treated population. †One additional participant in the nicotine patch group (psychiatric cohort) who reported moderate suicidal ideation (serious adverse events) was identified after the clinical database was locked; consequently, it was not included in the analysis of the primary study endpoint. ‡Grade=severe intensity adverse events. §Grade=moderate and severe intensity adverse event. ¶Serious adverse events were: *Non-psychiatric cohort*: bupropion, suicide attempt; nicotine patch, suicide attempt, panic; placebo, suicidal ideation (2), completed suicide; *Psychiatric cohort*: varenicline, suicidal ideation (2), depression, auditory hallucination, exacerbation of bipolar I disorder, anxiety plus self-injurious behaviour; bupropion, suicide attempt plus schizoaffective disorder, exacerbations of bipolar I disorder (2) and bipolar II disorder, emotional disorder plus neuropsychiatric symptoms; nicotine patch, anxiety (2), depression; placebo, suicide attempt, suicidal ideation, aggression. **Interventions include: psychotropic medication, psychotherapy, counselling, and hospitalisation.

Table 3: Columbia-Suicide Severity Rating Scale

	Non-psychiatric cohort* (N=3984)				Psychiatric cohort* (N=4074)			
	Varenicline (n=990)	**Bupropion (n=989)**	**Nicotine patch (n=1006)**	**Placebo (n=999)**	**Varenicline (n=1026)**	**Bupropion (n=1017)**	**Nicotine patch (n=1016)**	**Placebo (n=1015)**
During treatment and ≤30 days after last dose								
Assessed	988	983	996	995	1017	1012	1006	1006
Suicidal behaviour and/or ideation	7 (0·7%)	4 (0·4%)	3 (0·3%)	7 (0·7%)	27 (2·7%)	15 (1·5%)	20 (2·0%)	25 (2·5%)
Suicidal behaviour†‡	0 (0%)	0 (0%)	1 (0·1%)	1 (0·1%)§	0 (0%)	1 (0·1%)	0 (0%)	2 (0·2%)
Suicidal ideation	7 (0·7%)	4 (0·4%)	3 (0·3%)	6 (0·6%)	27 (2·7%)	15 (1·5%)	20 (2·0%)	25 (2·5%)
During follow-up (>30 days after last treatment dose and through end of study)								
Assessed	807	816	800	805	833	836	824	791
Suicidal behaviour and/or ideation	3 (0·4%)	2 (0·2%)	3 (0·4%)	4 (0·5%)	14 (1·7%)	4 (0·5%)	9 (1·1%)	11 (1·4%)
Suicidal behaviour†¶	0 (0%)	1 (0·1%)	0 (0%)	0 (0%)	1 (0·1%)	0 (0%)	1 (0·1%)	1 (0·1%)
Suicidal ideation	3 (0·4%)	2 (0·2%)	3 (0·4%)	4 (0·5%)	14 (1·7%)	4 (0·5%)	9 (1·1%)	11 (1·4%)

Data are n or n (%). *All-treated population. †Suicidal behaviour (most severe for each participant with positive answers on the C-SSRS). ‡During treatment: *Non-psychiatric cohort* – nicotine patch, suicide attempt (1); placebo, completed suicide (1); *Psychiatric cohort* – bupropion, suicide attempt (1); placebo, suicide attempt (2). §Completed

suicide. ¶During follow-up: *Non-psychiatric cohort* – bupropion, suicide attempt (1); *Psychiatric cohort* – varenicline, suicide attempt (1); nicotine patch, aborted attempt (1); placebo, aborted attempt (1).

Table 4: Mild, moderate, or severe adverse events* coding to the MedDRA category psychiatric disorders reported by ≥1% of participants in any treatment group

	Non-psychiatric cohort† (N=3984)				Psychiatric cohort† (N=4074)			
	Varenicline (n=990)	Bupropion (n=989)	Nicotine patch (n=1006)	Placebo (n=999)	Varenicline (n=1026)	Bupropion (n=1017)	Nicotine patch (n=1016)	Placebo (n=1015)
Psychiatric disorders	315 (31·8%)	332 (33·6%)	301 (29·9%)	259 (25·9%)	405 (39·5%)	435 (42·8%)	420 (41·3%)	354 (34·9%)
Abnormal dreams	83 (8·4%)	47 (4·8%)	111 (11·0%)	39 (3·9%)	118 (11·5%)	84 (8·3%)	140 (13·8%)	53 (5·2%)
Agitation	32 (3·2%)	29 (2·9%)	28 (2·8%)	25 (2·5%)	47 (4·6%)	56 (5·5%)	39 (3·8%)	41 (4·0%)
Anger	3 (0·3%)	1 (0·1%)	1 (0·1%)	3 (0·3%)	11 (1·1%)	4 (0·4%)	4 (0·4%)	5 (0·5%)
Anxiety‡	46 (4·6%)	64 (6·5%)	45 (4·5%)	57 (5·7%)	86 (8·4%)	105 (10·3%)	93 (9·2%)	63 (6·2%)
Depressed mood	31 (3·1%)	13 (1·3%)	27 (2·7%)	29 (2·9%)	47 (4·6%)	47 (4·6%)	52 (5·1%)	52 (5·1%)
Depression	17 (1·7%)	13 (1·3%)	8 (0·8%)	15 (1·5%)	49 (4·8%)	45 (4·4%)	47 (4·6%)	46 (4·5%)
Depressive symptom	5 (0·5%)	3 (0·3%)	2 (0·2%)	2 (0·2%)	11 (1·1%)	8 (0·8%)	12 (1·2%)	13 (1·3%)
Initial insomnia	7 (0·7%)	6 (0·6%)	10 (1·0%)	4 (0·4%)	15 (1·5%)	8 (0·8%)	10 (1·0%)	2 (0·2%)
Insomnia	95 (9·6%)	126 (12·7%)	91 (9·0%)	73 (7·3%)	94 (9·2%)	119 (11·7%)	104 (10·2%)	66 (6·5%)
Irritability	34 (3·4%)	29 (2·9%)	47 (4·7%)	37 (3·7%)	48 (4·7%)	42 (4·1%)	61 (6·0%)	67 (6·6%)
Major depression	3 (0·3%)	0 (0%)	1 (0·1%)	3 (0·3%)	7 (0·7%)	10 (1·0%)	4 (0·4%)	2 (0·2%)

Middle insomnia	7 (0·7%)	15 (1·5%)	13 (1·3%)	6 (0·6%)	11 (1·1%)	16 (1·6%)	13 (1·3%)	8 (0·8%)
Nervousness	14 (1·4%)	18 (1·8%)	11 (1·1%)	9 (0·9%)	21 (2·0%)	19 (1·9%)	17 (1·7%)	27 (2·7%)
Nightmare	9 (0·9%)	7 (0·7%)	26 (2·6%)	3 (0·3%)	13 (1·3%)	9 (0·9%)	30 (3·0%)	14 (1·4%)
Panic attack	2 (0·2%)	7 (0·7%)	2 (0·2%)	3 (0·3%)	9 (0·9%)	19 (1·9%)	13 (1·3%)	11 (1·1%)
Restlessness	14 (1·4%)	14 (1·4%)	15 (1·5%)	14 (1·4%)	17 (1·7%)	20 (2·0%)	14 (1·4%)	9 (0·9%)
Sleep disorder	31 (3·1%)	37 (3·7%)	17 (1·7%)	19 (1·9%)	34 (3·3%)	36 (3·5%)	28 (2·8%)	23 (2·3%)
Tension	2 (0·2%)	10 (1·0%)	2 (0·2%)	2 (0·2%)	9 (0·9%)	5 (0·5%)	10 (1·0%)	6 (0·6%)

Data are n (%).*As classified by the Medical Dictionary for Regulatory Activities (MedDRA, v18.0) in the System Organ Class category of psychiatric disorders and derived preferred terms, and occurring during treatment and ≤30 days after last dose. †All-treated population. ‡As per MedDRA (v18.0) preferred term "Anxiety". Note, this differs from the "Anxiety" component of the primary composite endpoint, which is a cluster of several MedDRA (v18.0) preferred terms related to anxiety disorders. Same note applies to other preferred terms in this table (e.g., depression, agitation).

Figure 1


A Non-psychiatric cohort
11,186 Assessed for eligibility
3042 Excluded
2482 Not meeting inclusion criteria
282 Declined to participate
278 Other reasons
8144 Participants randomised
Non-psychiatric cohort
4028 Participants randomised
Psychiatric cohort
4116 Participants randomised
(see Figure 2B)
1005 Randomised to varenicline
990 Treated
15 Not treated
7 Lost to follow-up
1 No longer meet eligibility criteria
4 No longer willing to participate
3 Other reasons
1001 Randomised to bupropion
989 Treated
12 Not treated
1 No longer meet eligibility criteria
9 No longer willing to participate
1 Protocol violation
1 Other reasons
1013 Randomised to nicotine patch
1006 Treated
7 Not treated
7 No longer willing to participate
1009 Randomised to placebo
999 Treated
10 Not treated
3 Lost to follow-up
1 No longer meet eligibility criteria
4 No longer willing to participate
2 Other reasons
787 Completed study
203 Discontinued after treatment start
139 During treatment phase
44 Lost to follow-up
12 Adverse event
3 Insufficient clinical response
64 No longer willing to participate
1 Withdrawn due to pregnancy
15 Other reasons
64 During follow-up phase
24 Lost to follow up
2 Adverse event
1 No longer meet eligibility criteria
30 No longer willing to participate
7 Other reasons
783 Completed study
206 Discontinued after treatment start
130 During treatment phase
39 Lost to follow-up
10 Adverse event
2 Insufficient clinical response
3 No longer meet eligibility criteria
64 No longer willing to participate
1 Medication error
1 Subject died
10 Other reasons
76 During follow-up phase
28 Lost to follow up
2 Adverse event
1 Insufficient clinical response
39 No longer willing to participate
1 Protocol violation
5 Other reasons
767 Completed study
239 Discontinued after treatment start
157 During treatment-phase
37 Lost to follow up
21 Adverse event
5 Insufficient clinical response
1 No longer meet eligibility criteria
82 No longer willing to participate
3 Protocol violation
8 Other reasons
82 During follow-up phase
35 Lost to follow up
1 Adverse event
3 Insufficient clinical response
1 No longer meet eligibility criteria
36 No longer willing to participate
6 Other reasons
787 Completed study
212 Discontinued after treatment start
154 During treatment phase
39 Lost to follow-up
8 Adverse event
3 Insufficient clinical response
2 No longer meet eligibility criteria
91 No longer willing to participate
2 Protocol violation
1 Withdrawn due to pregnancy
1 Subject died
7 Other reasons
58 During follow-up phase
20 Lost to follow up
2 No longer meet eligibility criteria
33 No longer willing to participate
1 Subject died
2 Other reasons
1005 Included in efficacy analyses
990 Included in safety analyses
1001 Included in efficacy analyses
989 Included in safety analyses
1013 Included in efficacy analyses
1006 Included in safety analyses
1009 Included in efficacy analyses
999 Included in safety analyses
B Psychiatric cohort
11,186 Assessed for eligibility
3042 Excluded
2482 Not meeting inclusion criteria
282 Declined to participate
278 Other reasons
8144 Participants randomised
Non-psychiatric cohort
4028 Participants randomised
(see Figure 2A)
Psychiatric cohort
4116 Participants randomised
1032 Randomised to varenicline
1026 Treated
6 Not treated
1 Lost to follow-up
5 No longer willing to participate
1033 Randomised to bupropion
1017 Treated
16 Not treated
3 Lost to follow-up
1 Adverse event
1 No longer meet eligibility criteria
8 No longer willing to participate
1 Protocol violation
2 Other reasons
1025 Randomised to nicotine patch
1016 Treated
9 Not treated
1 Adverse event
5 No longer willing to participate
1 Protocol violation
1 Subject died
1 Other reasons
1026 Randomised to placebo
1015 Treated
11 Not treated
3 Lost to follow-up
8 No longer willing to participate
811 Completed study
215 Discontinued after treatment start
154 During treatment phase
48 Lost to follow-up
20 Adverse event
1 Insufficient clinical response
2 No longer meet eligibility criteria
65 No longer willing to participate
4 Protocol violation
14 Other reasons
61 During follow-up phase
19 Lost to follow-up
1 No longer meet eligibility criteria
36 No longer willing to participate
5 Other reasons
803 Completed study
214 Discontinued after treatment start
151 During treatment phase
39 Lost to follow-up
16 Adverse event
1 Insufficient clinical response
4 No longer meet eligibility criteria
81 No longer willing to participate
1 Protocol violation
1 Subject died
8 Other reasons
63 During follow-up phase
20 Lost to follow-up
1 No longer meet eligibility criteria
34 No longer willing to participate
1 Subject died
7 Other reasons
790 Completed study
226 Discontinued after treatment start
146 During treatment phase
38 Lost to follow-up
12 Adverse event
5 Insufficient clinical response
3 No longer meet eligibility criteria
72 No longer willing to participate
1 Protocol violation
15 Other reasons
80 During follow-up phase
34 Lost to follow-up
1 Adverse event
1 Insufficient clinical response
1 No longer meet eligibility criteria
34 No longer willing to participate
1 Protocol violation
1 Subject died
7 Other reasons
765 Completed study
250 Discontinued after treatment start
181 During treatment phase
44 Lost to follow-up
17 Adverse event
8 Insufficient clinical response
1 No longer meet eligibility criteria
90 No longer willing to participate
1 Medication error
3 Protocol violation
1 Subject died
16 Other reasons
69 During follow-up phase
24 Lost to follow-up
1 Adverse event
2 Insufficient clinical response
34 No longer willing to participate
8 Other reasons
1032 Included in efficacy analyses
1026 Included in safety analyses
1033 Included in efficacy analyses
1017 Included in safety analyses
1025 Included in efficacy analyses
1016 Included in safety analyses
1026 Included in efficacy analyses
1015 Included in safety analyses

Figure 2



	Non-psychiatric cohort (N=4028) Varenicline (n=1005) Bupropion (n=1001) Nicotine patch (n=1013) Placebo (n=1009)		**Psychiatric cohort (N=4116)** Varenicline (n=1032) Bupropion (n=1033) Nicotine patch (n=1025) Placebo (n=1026)		**Overall (N=8144)** Varenicline (n=2037) Bupropion (n=2034) Nicotine patch (n=2038) Placebo (n=2035)	
OR (95% CI) p value	**Weeks 9–12**	**Weeks 9–24**	**Weeks 9–12**	**Weeks 9–24**	**Weeks 9–12**	**Weeks 9–24**
Primary comparisons						
Varenicline *vs* placebo	4·00 (3·20–5·00) p<0·0001	2·99 (2·33–3·83) p<0·0001	3·24 (2·56–4·11) p<0·0001	2·50 (1·90–3·29) p<0·0001	3·61 (3·07–4·24) p<0·0001	2·74 (2·28–3·30) p<0·0001
Bupropion *vs* placebo	2·26 (1·80–2·85) p<0·0001	2·00 (1·54–2·59) p<0·0001	1·87 (1·46–2·39) p<0·0001	1·77 (1·33–2·36) p<0·0001	2·07 (1·75–2·45) p<0·0001	1·89 (1·56–2·29) p<0·0001
Secondary comparisons						
Nicotine patch *vs* placebo	2·30 (1·83–2·90) p<0·0001	1·96 (1·51–2·54) p<0·0001	2·00 (1·56–2·55) p<0·0001	1·65 (1·24–2·20) p=0·0007	2·15 (1·82–2·54) p<0·0001	1·81 (1·49–2·19) p<0·0001
Varenicline *vs* nicotine patch	1·74 (1·43–2·10) p<0·0001	1·52 (1·23–1·89) p=0·0001	1·62 (1·32–1·99) p<0·0001	1·51 (1·19–1·93) p=0·0008	1·68 (1·46–1·93) p<0·0001	1·52 (1·29–1·78) p<0·0001
Bupropion *vs* nicotine patch	0·98 (0·80–1·20) p=0·8701	1·02 (0·81–1·28) p=0·8645	0·94 (0·75–1·16) p=0·5467	1·07 (0·83–1·39) p=0·5824	0·96 (0·83–1·11) p=0·5797	1·04 (0·88–1·24) p=0·6002
Varenicline *vs* bupropion	1·77 (1·46–2·14) p<0·0001	1·49 (1·20–1·85) p=0·0003	1·74 (1·41–2·14) p<0·0001	1·41 (1·11–1·79) p=0·0047	1·75 (1·52–2·01) p<0·0001	1·45 (1·24–1·70) p<0·0001